Reslizumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | IL-5 |
| Identifiers | |
| ATC code | none |
Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract.[1] As of September 2009[update], the drug is undergoing Phase II/III clinical trials.[2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ Walsh, GM (2009). "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions". Current opinion in molecular therapeutics. 11 (3): 329–36. PMID 19479666.
- ↑ ClinicalTrials.gov
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from September 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
